What is Intercept Pharmaceuticals, Inc. (ICPT) stock price today?

Intercept Pharmaceuticals, Inc. (ICPT) is currently trading at $19.00, up 0.21% today.

What is ICPT P/E ratio?

Intercept Pharmaceuticals, Inc.'s P/E ratio is 5.57. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ICPT return on equity (ROE)?

Intercept Pharmaceuticals, Inc.'s return on equity (ROE) is -253.45%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Intercept Pharmaceuticals, Inc.'s market cap?

Intercept Pharmaceuticals, Inc. has a market capitalization of $794.69M.

NASDAQ · Biotechnology

Intercept Pharmaceuticals, Inc. (ICPT) Stock

$19.00 +0.21% NASDAQ: ICPT Healthcare

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions.

Valuation

Metric	Value
Price	$19.00
Market Cap	$794.69M
P/E Ratio	5.57
P/B Ratio	6.90
P/S Ratio	2.78
EPS (TTM)	$3.41
52-Week High	$21.86
52-Week Low	$8.82
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-253.45%
ROA	20.80%
ROCE	-21.08%
Gross Margin	99.66%
Operating Margin	-23.88%
Net Margin	40.31%
Debt/Equity	3.57
Current Ratio	2.35

Annual Financials (USD)

Metric	2018	2019	2020	2021	2022
Revenue	$180.0M	$252.0M	$313.0M	$363.0M	$286.0M
Operating Profit	$-285.0M	$-312.0M	$-217.0M	$-56.0M	$-68.0M
Net Profit	$-309.0M	$-391.0M	$-324.0M	$-145.0M	$115.0M
EPS	$-10.86	$-12.35	$-9.83	$-4.55	$3.40
Op Margin	-158.8%	-124.0%	-69.3%	-15.3%	-23.9%

Balance Sheet (USD)

Metric	2018	2019	2020	2021	2022
Total Assets	$509.0M	$755.0M	$580.0M	$527.0M	$554.0M
Total Liabilities	$490.0M	$703.0M	$747.0M	$711.0M	$461.0M
Cash	$436.0M	$70.0M	$58.0M	$85.0M	$51.0M
Borrowings	$371.0M	$539.0M	$576.0M	$547.0M	$333.0M

Cash Flow (USD)

Metric	2018	2019	2020	2021	2022
Operating Cash Flow	$-241.0M	$-237.0M	$-170.0M	$-42.0M	$-27.0M
Investing Cash Flow	$-96.0M	$-190.0M	$159.0M	$70.0M	$261.0M
Financing Cash Flow	$261.0M	$455.0M	$-3.0M	$-75.0M	$-268.0M
Net Cash Flow	$-27.0M	$32.0M	$-9.0M	$29.0M	$-39.0M
Free Cash Flow	$-241.0M	$-238.0M	$-174.0M	$-42.0M	$-27.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.04
EV / EBITDA	-17.45
FCF Yield	-3.44%
Quick Ratio	2.35
Interest Coverage	-3.19
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ALBOAlbireo Pharma, Inc.	$44.15	+0.00%	-5.61	$915.89M	0.00%
ASLNASLAN Pharmaceuticals Limited	$0.60	-14.27%	-0.06	$777.12M	0.00%
CDMOAvid Bioservices, Inc.	$12.49	+0.00%	-5.60	$798.90M	0.00%
CMRXChimerix, Inc.	$8.54	+0.00%	-8.63	$801.08M	0.00%
EXAIExscientia plc	$4.84	—	-3.06	$633.18M	0.00%

About Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.

Intercept Pharmaceuticals, Inc. is headquartered in US.

Intercept Pharmaceuticals, Inc. (ICPT) stock trades at $19.00 with a market capitalization of $794.69M. The stock is valued at a price-to-earnings (P/E) ratio of 5.57, price-to-book of 6.90, price-to-sales of 2.78. Over the past 52 weeks the stock has ranged between $8.82 and $21.86, and currently trades 13.1% below its 52-week high.

On profitability, Intercept Pharmaceuticals, Inc. generates a return on equity (ROE) of -253.45%, return on capital employed of -21.08%, an operating margin of -23.88%, a net profit margin of 40.31%.

Official website: www.interceptpharma.com